Biosimilars of filgrastim in autologous stem cell transplantation: certain differences for myeloma patients only

Leuk Lymphoma. 2017 Sep;58(9):1-3. doi: 10.1080/10428194.2017.1285025. Epub 2017 Feb 7.

Affiliations

¹ a Service d'Hématologie , Institut de Cancéro-Hématologie, Hôpital Morvan, CHRU de Brest , Brest Cedex , France.
² b Service d'Onco-Pédiatrie , Hôpital Morvan, CHRU de Brest , Brest Cedex , France.
³ c Etablissement Français du Sang , Site de Brest, CHRU de Brest , Brest Cedex , France.
⁴ d Laboratoire d'Hématologie , Hôpital de la Cavale Blanche, CHRU de Brest , Brest Cedex , France.

PMID: 28278727
DOI: 10.1080/10428194.2017.1285025

No abstract available

Publication types

Letter

MeSH terms

Biosimilar Pharmaceuticals*
Female
Filgrastim / administration & dosage
Filgrastim / therapeutic use*
Granulocyte Colony-Stimulating Factor / administration & dosage
Granulocyte Colony-Stimulating Factor / therapeutic use
Hematopoietic Stem Cell Transplantation* / adverse effects
Hematopoietic Stem Cell Transplantation* / methods
Humans
Male
Multiple Myeloma / diagnosis
Multiple Myeloma / mortality
Multiple Myeloma / therapy*
Postoperative Care
Recombinant Proteins
Transplantation, Autologous
Treatment Outcome

Substances

Biosimilar Pharmaceuticals
Recombinant Proteins
Granulocyte Colony-Stimulating Factor
Filgrastim